Innovation Health, an innovation partnership between Inova and Aetna has announced a new pilot program with Sanofi for people living with Type 2 diabetes. The focus of the pilot program will work to study the impact of novel digital helath solutions from One Drop and Gocap to help patient outcomes and medication adherence. The pilot program will be facilitated by Innovation Health, Inova Health Systems and Healthagen, a division of Aetna.
Digital Therapeutic Pilot Program Overview
The goal of the type 2 diabetes pilot program is for pharmaceutical companies, technology companies and plan providers to work more closely together to help improve patient outcomes. To achieve this, the pilot program will utilize two digital health technologies:
– One Drop, an evidence-based, clinically effective diabetes self-management platform, which includes a Bluetooth enabled blood glucose monitor, ADA recognized diabetes coaching and education and an award winning mobile app. The One Drop platform measures, stores, analyzes and transmits participant’s blood glucose, medication, diet and physical activity directly to the cloud.
Participants can communicate with their coaches anytime 24/7, via in-app chat. All data recorded in the app is available to coaches in real-time, allowing them to provide personalized guidance when participants need it most.
– Common Sensing’s Gocap is a low effort way to provide clinicians with real-life feedback on what people are doing with their insulin. The Gocap Clinical Dashboard highlights easy, high-value ways to connect with patients who are struggling with insulin use, and does so at the right time to adjust treatment strategies.
A recent study involving Gocap and Continuous Glucose Monitoring showed that care providers gleaned actionable insights for almost every patient using insulin with Gocap. By providing direct data about insulin use, the Gocap closes the gap between patient experience and physician knowledge.
The findings of the pilot will be analyzed to gain insights into potential best practices for industry arrangements and overall treatment of people living with diabetes.
“As a leader in diabetes, our ambition is to empower people with diabetes to live the life they want,” said Vice President of Innovative Solutions, US DCV at Sanofi, Sebastien Coisne in a statement. “We believe that combining innovative medicines with connected devices and solutions leads to better patient outcomes and an improved patient experience. As innovative solutions come to market, we are very excited to work with Innovation Health on this pilot program and trust it will provide further insights to achieve that goal.”
